Nuo Therapeutics Inc
OTC:AURX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.1
3.23
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Nuo Therapeutics Inc
OTC:AURX
|
89m USD |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.2B USD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
40.5B USD |
Loading...
|
|
| US |
|
Gartner Inc
NYSE:IT
|
16.8B USD |
Loading...
|
|
| IE |
|
ICON PLC
NASDAQ:ICLR
|
13.9B USD |
Loading...
|
|
| US |
|
Ionis Pharmaceuticals Inc
NASDAQ:IONS
|
12.3B USD |
Loading...
|
|
| US |
|
Charles River Laboratories International Inc
NYSE:CRL
|
10.8B USD |
Loading...
|
|
| US |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
8.4B USD |
Loading...
|
|
| US |
|
Cytokinetics Inc
NASDAQ:CYTK
|
7.6B USD |
Loading...
|
|
| UK |
|
Verona Pharma PLC
NASDAQ:VRNA
|
7.4B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Nuo Therapeutics Inc
Glance View
Nuo Therapeutics, Inc. is a biomedical company. The company is headquartered in Houston, Texas and currently employs 7 full-time employees. The company went IPO on 2017-01-19. The firm's Aurix System is a biodynamic hematogel that harnesses a patient's innate regenerative abilities for the management of a variety of wounds. The firm commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company’s Aurix point of care technology for the safe and efficient separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. The firm is marketing its products primarily within the United States. Nuo Therapeutics' s Aurix System produces a platelet rich plasma (PRP), gel at the point of care using the patient’s own platelets and plasma. The Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Nuo Therapeutics Inc is -93.1%, which is above its 3-year median of -742.4%.
Over the last 3 years, Nuo Therapeutics Inc’s Net Margin has increased from -7 700% to -93.1%. During this period, it reached a low of -7 700% on Aug 30, 2022 and a high of -93.1% on Oct 30, 2025.